| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9311817 | Urology | 2005 | 5 Pages |
Abstract
LVI is an independent prognostic factor for recurrence-free survival in transitional cell carcinoma of the upper urinary tract. Because LVI is strongly associated with a poorer prognosis, systemic adjuvant therapy should be considered in the presence of LVI, even if the lymph nodes are not involved.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Bumsik Hong, Sungchan Park, Jun Hyuk Hong, Choung-Soo Kim, Jae Y. Ro, Hanjong Ahn,